Alert detail
FDA Approval: Unknown (Unknown) — Type 5 - New Formulation or New Manufacturer
Policy ID: FDA-NDA217379Specialty: OncologyAdded: 6/5/2026Effective: 2026-05-29federal register
What changed
Cavhanza (Nilotinib) is a new oral medication for 2026.
Who’s affected: Oncology billing teams · Effective: 2026-05-29
Primary source: View the official CMS/MAC document ↗
Get the action steps and full analysis
Subscribers get the recommended action (“what to do”), the full AI analysis, the LCD revision comparison, and related alerts across your specialty and jurisdiction.
Not ready to subscribe?
Get the free weekly reimbursement brief for Oncology— the week’s changes and deadlines, delivered to your inbox. No account required.